Myeloproliferative disorders are a group of stem cell disorders that can affect the production of red blood cells, white blood cells and/or platelets. Although rare, they are often diagnosed within general practice, most often incidentally, and are therefore important conditions for which primary care clinicians need to have a good understanding. This article aims to provide a clear and concise summary of what myeloproliferative disorders are, how they can present, how to investigate them, when to involve secondary care and what potential complications need to be paid attention.
Get full access to this article
View all access options for this article.
References
1.
ArberDOraziAHasserjianR, et al. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood127(20): 2391–2405. DOI: 10.1182/blood-2016-03-64354.
2.
BarbuiTFinazziGCarobbioA, et al. (2012) Development and validation of an international prognostic score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood120(26): 5128–5133. DOI: 10.1182/blood-2012-07-444067.
3.
BarbuiTThieleJGisslingerH, et al. (2016) The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Reviews30(6): 453–459. DOI: 10.1016/j.blre.2016.06.001.
4.
CerquozziSTefferiA (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: A literature review of incidence and risk factors. Blood Cancer Journal5(11): e366DOI:10.1038/bcj.2015.95.
5.
ChimCKwongYLieAK, et al. (2005) Long-term outcome of 231 patients with essential thrombocythemia: Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Archives of Internal Medicine165(22): 2651–2658. DOI: 10.1001/archinte.165.22.2651.
6.
FenauxPSimonMCaulierMT, et al. (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer66(3): 549–556. DOI: 10.1002/1097-0142(19900801)66:3<549::aid-cncr2820660324>3.0.co;2-6.
7.
GirodonFBonicelliGSchaefferC, et al. (2009) Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: A population-based study. Haematologica94(6): 865–869. DOI:10.3324/haematol.2008.004234.
8.
HochhausALarsonRGuilhotF, et al. (2017) Long-term outcomes of Imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine376: 917–927. DOI: 10.1056/NEJMoa1609324.
9.
HöglundMSandinFSimonssonB (2015) Epidemiology of chronic myeloid leukaemia: An update. Annals of Haematology94(2): 241–247. DOI: 10.1007/s00277-015-2314-2.
10.
LandolfiRDi GennaroLFalangaA (2008) Thrombosis in myeloproliferative disorders: Pathogenetic facts and speculation. Leukemia22: 2020–2028. DOI: 10.1038/leu.2008.25.
11.
LevineRLWadleighMCoolsJ, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell7(4): 387–397. DOI: 10.1016/j.ccr.2005.03.023.
12.
MarchioliRFinazziGLandolfiR, et al. (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Journal of Clinical Oncology23(10): 2224–2232. DOI: 10.1200/JCO.2005.07.062.
13.
MoulardOMehtaJFryzekJ, et al. (2014) Epidemiology of myelofibrosis, essential thrombocythaemia, and polycythaemia vera in the European Union. European Journal of Haematology92(4): 289–297. DOI: 10.1111/ejh.12256.
14.
NICE (2020) Suspected cancer: Recognition and referral. Available at: www.nice.org.uk/guidance/ng12 (accessed 14 February 2022).
15.
Provan D, Baglin T, Dokal I, et al. (2015) Oxford Medical Handbook of Clinical Haematology, fourth edition. Oxford: Oxford University Press.
SankarKPettitK (2020) Non-pharmacologic management of splenomegaly for patients with myelofibrosis: Is there any role for splenectomy or splenic radiation in 2020?Current Hematologic Malignancy Reports15(5): 391–400. DOI: 10.1007/s11899-020-00598-x.
20.
SmalbergJArendsLRVallaDC, et al. (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: A meta-analysis. Blood120(25): 4921–4928. DOI: 10.1182/blood-2011-09-376517.
21.
TefferiA (2014) Primary myelofibrosis: Update on diagnosis, risk-stratification, and management. American Journal of Hematology89: 915–925. DOI: 10.1002/ajh.23703.
22.
TefferiAGuglielmelliPLarsonDR, et al. (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood124(16): 2507–2513. DOI: 10.1182/blood-2014-05-579136.
23.
TefferiARumiEFinazziG (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia27(9): 1874–1881. DOI: 10.1038/leu.2013.163.
24.
WangYVandrisKJonesA, et al. (2008) JAK2 mutations are present in all cases of polycythemia vera. Leukemia22(6): 1289DOI: 10.1038/sj.leu.2405047.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
